


## PHARMACEUTICAL 2022

## Greenwich LifeSciences Inc. Rank 78 of 475





## PHARMACEUTICAL 2022



## Greenwich LifeSciences Inc. Rank 78 of 475

The relative strengths and weaknesses of Greenwich LifeSciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Greenwich LifeSciences Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 2,209% points. The greatest weakness of Greenwich LifeSciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 79%, being 356% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	13
Liabilities, Current	385
Liabilities, Non-Current	0
Other Assets	27,204
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	27
Property and Equipment	0
Research and Development	3,560
Revenues	0
Selling, General and Administrative Expense	1,038

Output Variable	Value in 1000 USD
Assets	27,217
Liabilities	385
Expenses	4,598
Stockholders Equity	26,832
Net Income	-4,571
Comprehensive Net Income	-4,571
Economic Capital Ratio	79%